News and commentary from the world of gastroenterology and hepatology
— News and commentary from the world of gastroenterology and hepatology
by Ian Ingram, Managing Editor, MedPage Today
May 28, 2026
• 2 min read
A real-world study of chronic pancreatitis found GLP-1 agonists to be associated with less pain medication use and lower risks for pancreatic interventions, including major surgery. (Gastro Hep Advances)
The Next Frontier For GLP-1 Medications: Potential Therapy For Inflammation
People with eating disorders are taking GLP-1s, and doctors are alarmed
I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
Ahead of ASCO, all eyes on pancreatic cancer
News and commentary from the world of gastroenterology and hepatology
Studies show that GLP-1 receptor agonists have significant potential for treating glaucoma, diabetic retinopathy and other eye…
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients…
According to a new study, GLP-1s may be potentially effective in reducing chronic inflammation.
Agency updates guidance after increase in reports of condition to the yellow card scheme
Early data are promising, but GLP-1 drugs aren't yet recommended as IBD therapy
